MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer

Takahiro Maeda, Masayuki Hiraki, Caining Jin, Hasan Rajabi, Ashujit Tagde, Maroof Alam, Audrey Bouillez, Xiufeng Hu, Yozo Suzuki, Masaaki Miyo, Tsuyoshi Hata, Kunihiko Hinohara, Donald Kufe

Research output: Contribution to journalArticlepeer-review

138 Citations (Scopus)


The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis. Here, we report that genetic or pharmacological targeting of the oncogenic MUC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells. Mechanistic investigations showed that MUC1-C acted to elevate PD-L1 transcription by recruitment of MYC and NF-kB p65 to the PD-L1 promoter. In an immunocom-petent model of TNBC in which Eo771/MUC1-C cells were engrafted into MUC1 transgenic mice, we showed that targeting MUC1-C associated with PD-L1 suppression, increases in tumor-infiltrating CD8þ T cells and tumor cell killing. MUC1 expression in TNBCs also correlated inversely with CD8, CD69, and GZMB, and downregulation of these markers associated with decreased survival. Taken together, our findings show how MUC1 contributes to immune escape in TNBC, and they offer a rationale to target MUC1-C as a novel immunotherapeutic approach for TNBC treatment. Significance: These findings show how upregulation of the transmembrane mucin MUC1 contributes to immune escape in an aggressive form of breast cancer, with potential implications for a novel immunotherapeutic approach.

Original languageEnglish
Pages (from-to)205-215
Number of pages11
JournalCancer Research
Issue number1
Publication statusPublished - Jan 1 2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this